Oriented attachment of VNAR proteins, Q2 via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance

Joao C. F. Nogueira, Michelle K. Greene, Daniel A. Richards, Alexander O. Furby, John Steven, Andrew Porter, Caroline Barelle (Corresponding Author), Christopher J. Scott (Corresponding Author), Vijay Chudasama (Corresponding Author)

Research output: Contribution to journalArticle

4 Citations (Scopus)
7 Downloads (Pure)

Abstract

Herein we report the construction of a nanoparticle-based drug delivery system which targets a key regulator in tumour angiogenesis. We exploit a Variable New Antigen Receptor (VNAR) domain, conjugated using site-specific chemistry, to direct poly lactic acidco-glycolic acid–polyethylene glycol (PLGA–PEG) nanoparticles to delta like canonical Notch ligand 4 (DLL4). The importance of sitespecific chemistry is demonstrated.
Original languageEnglish
Pages (from-to)7671-7674
Number of pages4
JournalChemical Communications
Volume55
Issue number53
Early online date29 May 2019
DOIs
Publication statusPublished - 7 Jul 2019

Keywords

  • MONOCLONAL-ANTIBODY
  • TARGETED DELIVERY
  • FRAGMENTS
  • OPTIMIZATION
  • INSTALLATION
  • CONJUGATION
  • DRUGS

Fingerprint Dive into the research topics of 'Oriented attachment of VNAR proteins, Q2 via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance'. Together they form a unique fingerprint.

  • Cite this

    Nogueira, J. C. F., Greene, M. K., Richards, D. A., Furby, A. O., Steven, J., Porter, A., Barelle, C., Scott, C. J., & Chudasama, V. (2019). Oriented attachment of VNAR proteins, Q2 via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance. Chemical Communications, 55(53), 7671-7674. https://doi.org/10.1039/c9cc02655j